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“The neutrophil-to-lymphocyte and platelet-
to-lymphocyte ratios predict efficacy of 
platinum-based chemotherapy in patients 
with metastatic triple negative breast 
cancer” 
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1. Introduction 
Breast cancer is the most common malignancy among 
women and also one of the leading causes of cancer 
related death (1).  
Breast cancer is a heterogeneous disease, comprising 
multiple entities associated with distinctive histological 
and biological features, clinical presentations and 
behaviors and responses to therapy (2).  
Among all breast cancers, 5 different molecular 
subtypes can be classified, basing on expression of 
estrogen receptor (ER), progesterone receptor (PR), 
and human epidermal growth factor receptor 2 
(HER2): Luminal A, Luminal B, Her-2/neu, Basal-
like- triple negative; Unclassified- normal breast-like 
(3,4).  
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Figure 1. Breast cancer intrinsic subtypes by gene 
expression profile 
 
It is generally recognized that currently, not all basal-
like breast cancers display a triple negative phenotype 
and not all basal-like breast cancers are stratified as 
basal-like tumors by gene expression profiling (5).  
Triple negative breast cancer is the term used to 
describe breast cancers that lack estrogen- and 
progesterone-receptor expression and do not 
overexpress HER2 by immunohistochemistry.  
The definition of negative ER/PR status is not 
concordant in the literature, with some definitions 
considering ER/PR expression to be significant only if 
at least 10% of tumor cells express the receptors. 
However, the St. Gallen guidelines (6), the American 
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Society of Clinical Oncology (7), and the American 
College of Pathology (8) have defined triple negative 
breast cancer as breast cancer with less than 1% of 
tumor cells expressing ER and PR via 
immunohistochemistry.  
It is widely accepted that TNBC is a very 
inhomogeneous group; using gene expression analyses, 
6 distinct TNBC subtypes have been recently 
identified, each displaying a unique biology: basal-like 
1 and 2 (BL1 and BL2), immunomodulatory (IM),  
mesenchymal (M), mesenchymal stem-like (MSL), and 
luminal androgen receptor (LAR) subtype, the last 
being characterized by androgen receptor (AR) 
signaling (9).   
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Figure 2. Gene expression subtype classifications of triple 
negative breast cancer (TNBC).  
 
Metastatic triple negative breast cancer accounts for 
10–20% of all metastatic breast cancer cases, and is 
characterized by an aggressive course, the lack of 
therapeutic targets and high lethality (10,11). 
Even in recently published prospective trials, median 
progression free survival (PFS) and overall survival 
(OS) did not exceed 6 months and 12–18 months, 
respectively (12,13). 
Cytotoxic chemotherapy still remains the mainstay of 
treatment for triple negative breast cancer, both in 
adjuvant and in metastatic setting, and particularly 
taxane (paclitaxel, docetaxel, nabpaclitaxel) and 
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platinum salts (cisplatin and carboplatin) are 
considered among the most effective compounds in 
this breast cancer subgroup (12-17).  
Especially, platinum salts (specifically carboplatin) 
have been compared to docetaxel in metastatic triple 
negative breast cancer patients bearing germline 
mutations in BRCA1 or BRCA2 genes, showing greater 
response and progression free survival in favor of 
carboplatin over docetaxel, demonstrating clinical 
utility for treatment selection in this setting (14).  
These results suggest that platinum compounds could 
be preferred treatment options in this patient 
population (14).  
While such results await confirmation in larger studies, 
new predictive biomarkers are needed that are low-
cost, routinely assessable with standardized techniques, 
well reproducible across different laboratories, and 
capable of predicting benefit from platinum-based 
chemotherapy.  
Many evidences highlight the importance of immune 
system activation in control of this particular breast 
cancer subgroup: first, tumor-infiltrating lymphocytes 
(TILs) and other immune markers correlate with higher 
rates of pathological complete response (pCR), as well 
	 7	
as with better patient disease-free survival (DFS) and 
overall survival (OS), after neo-adjuvant chemotherapy 
(18-21); second, the programmed death 1 (PD-1) 
inhibitor Pembrolizumab (Keytruda®, Merck) and the 
PD-1 ligand (PD-L1) inhibitor Atezolizumab 
(Tecentriq®, Roche) are active in subgroups of heavily 
pre-treated TNBC patients (22-27). Moreover, in a 
recent phase 3 clinical trial, the combination of nab-
paclitaxel with atezolizumab as first-line treatment in 
triple negative metastatic breast cancer patients led to 
significantly longer progression-free survival than was 
seen with placebo plus nab-paclitaxel in both the 
intention-to-treat population and the subgroup of 
patients with PD-L1–positive tumors (27); to date, 
chemotherapy plus atezolizumab combinations are 
being evaluated in larger, prospective, phase 3 clinical 
trials [NCT03125902, NCT03371017, 
http://clinicaltrials.gov ]. 
Recent studies have revealed the prognostic role of 
parameters that reflect systemic inflammation or the 
status of antitumor immunity, such as the neutrophil-
to-lymphocyte ratio (NLR) and the platelet-to-
lymphocyte ratio (PLR), in different solid 
malignancies, including colorectal, renal and lung 
carcinomas (28, 29).  
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High NLR has also been associated with an increased 
risk of death in heterogeneous breast cancer patient 
populations (30), including patients with limited-stage 
triple negative breast cancer (31, 32).  
However, none of these studies specifically assessed 
the role of NLR in metastatic triple negative breast 
cancer and, even in those studies including different 
proportions of patients with metastatic breast cancer 
(4.2–13.9%), subgroup analyses in specific tumor 
biology subtypes, or based on the type of 
chemotherapy, were not reported. 
In this work, we assessed for the first time the potential 
role of NLR and PLR as biomarkers predictive of PFS 
in metastatic triple negative breast cancer patients 
treated with platinum-based chemotherapy. As a 
control population, we analyzed data from patients 
with hormone receptor positive, HER2 negative (ER 
positive/HER2 negative) metastatic breast cancer 
treated with the same platinum-containing regimens. 
To discriminate between a predictive and a purely 
prognostic role of these parameters, we also evaluated 
patient overall survival. 
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2. Methods 
2.1 Study setting  
This was a monocentric, retrospective study on patients 
with metastatic triple negative breast cancer treated 
between July 2007 and July 2017 at Fondazione 
IRCCS Istituto Nazionale dei Tumori placed in Milan, 
Italy, with platinum-based chemotherapy. The study 
was performed in accordance to relevant guidelines 
and regulations. Patients alive at the time of data 
collection and/or analysis signed an informed consent 
for the use of their personal data for research purposes. 
Eligibility criteria were: (a) age ≥18 years; (b) 
pathologically or cytologically confirmed diagnosis of 
unresectable, locally recurrent or metastatic TNBC, as 
defined by ER <1% and PgR <1% expression at 
immunohistochemistry (IHC) analysis and an IHC 
score for HER2 of 0, 1+, or 2+ with negative in situ 
hybridization (ISH); (c) ECOG performance status 
(PS) of 0–1; (d) treatment with one the following 
chemotherapy schedules: carboplatin area under the 
concentration-time curve (AUC) of 2 plus paclitaxel 80 
mg/m2, or carboplatin AUC 2 plus gemcitabine 800 
mg/m2, both given on days 1 and 8 of every-three 
weeks cycles; (e) availability of baseline (pre-
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treatment) absolute peripheral blood neutrophil, 
lymphocyte and platelet counts; (f) available 
information about previous treatment(s) for limited-
stage or advanced disease; (g) available information on 
the date of disease progression and on patient status 
(alive versus dead; date of death); (h) absence of acute 
infections or documented bone marrow infiltration at 
the time of peripheral blood cell count assessment. As 
a control population, we selected patients with ER 
positive/HER2 negative metastatic breast cancer 
treated with the same platinum-containing regimens in 
the July 2007-July 2017 decade at Fondazione IRCCS 
Istituto Nazionale dei Tumori, Milan (Italy). 
All subjects fulfilling these criteria were evaluated, 
regardless of line of treatment for metastatic breast 
cancer. 
2.2 Objectives.  
The main objective of the study was to investigate the 
potential association between baseline NLR/PLR and 
clinical outcome. The primary clinical endpoint was 
progression free survival (PFS), as defined as the time 
between treatment initiation and disease progression or 
death from any cause. Overall survival (OS) was a 
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secondary endpoint, and was defined as the time 
between treatment initiation and death from any cause. 
2.3 Assessment of response.  
Response was assessed every three cycles of 
chemotherapy, whereas tumor re-evaluation was 
anticipated in patients with worsening symptoms or 
other signs suggestive of progressive disease (PD). 
Tumor response was evaluated according to the 
Response Evaluation Criteria in Solid Tumors 
(RECIST version 1.1). Patients with only superficial, 
measurable disease were evaluated also clinically by 
measuring lesion diameters (with calipers) every three 
weeks. 
2.4 Evaluation of biomarkers.  
We collected data on absolute counts of peripheral 
blood neutrophils, lymphocytes, platelets and 
monocytes. We calculated the following parameters:  
(a) NLR by dividing neutrophil by lymphocyte counts;  
(b) PLR by dividing platelet by lymphocyte counts.  
As an exploratory analysis, we also assessed the 
lymphocyte-to-monocyte ratio (LMR).  
Blood parameters were evaluated before initiation of 
platinum-based chemotherapy. Parameters measured 
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within one month before the initiation of platinum-
based chemotherapy were considered acceptable, 
provided that the patient was not receiving any 
concomitant anticancer treatment. Patients whose 
blood parameters were measured more than one month 
before the date of chemotherapy initiation, or after 
having received the first dose of platinum-based 
treatment, were excluded from this study. As an 
exploratory analysis, we also evaluated the NLR and 
PLR before the administration of the third treatment 
cycle. 
2.5 Genetic analysis.  
Analysis of BRCA1/2 germline mutations was carried 
out on the DNA extracted from peripheral blood 
leukocytes. All coding exons and flanking regions of 
BRCA1 and BRCA2 genes were sequenced through 
direct sequencing, followed in most cases by multiple 
ligation-dependent probe amplification (MLPA) to 
detect large genomic rearrangements. Identified 
genetic variants were classified according to the IARC 
5-tier scheme, following the guidelines of the 
Evidence-based Network for the Interpretation of 
Germline Mutant Alleles (ENIGMA; 
http://enigmaconsortium.org/) (33). 
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2.6 Statistical analysis.  
Patients’ characteristics were analyzed by descriptive 
statistics. The χ2 or Fisher’s exact tests were used to 
assess the association between categorical variables, 
while linear correlation was used for continuous 
variables. Progression free survival (PFS) and overall 
survival (OS) were calculated according to the Kaplan-
Meier method, and the log-rank test was used to 
compare survival between different patient 
populations.  
The impact of known prognostic factors on PFS was 
first assessed at univariate analysis. Covariates 
significantly associated with the risk of progression (p 
< 0.1) were then included in a Cox proportional hazard 
model to assess their independent association with 
survival. 
Based on previously published data, the following 
categorical covariates were tested: (a) previous 
exposure to taxanes (yes vs no); (b) visceral disease 
(yes vs no); (c) the number of metastatic sites (1–2 vs 
>2); (d) having received maintenance treatment (yes vs 
no). The type of chemotherapeutical agent combined 
with carboplatin (i.e. gemcitabine vs paclitaxel) was 
also tested as a covariate. All statistical analyses were 
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performed using the software R (version 3.3.2 (2016-
10-31)), while the package “survival” was used for 
survival analyses. A p value of 0.05 was chosen as a 
threshold level for statistical significance. 
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3. Results 
3.1 Patient characteristics.  
Between July 2007 and July 2017, 62 metastatic triple 
negative breast cancer patients were treated at 
Fondazione IRCCS Istituto Nazionale dei Tumori, 
Milan (Italy) with platinum-based chemotherapy 
combinations. Among these patients, 57 fulfilled the 
inclusion criteria and were evaluable for the 
biomarkers of interest. At the moment of data lock and 
analysis, 53 (93%) patients had progressed and 48 
(84%) had died.  
Characteristics of evaluated patients are described in 
Table 1.  
 
Table 1. Characteristics of patients with metastatic TNBC 
and the ER-PgR positive/HER2 negative BC control 
population. 
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chemotherapeutical agents4–9. In a recent randomized study, carboplatin demonstrated superior activity com-
pared to docetaxel in mTNBC patients bearing germline mutations in BRCA1 or BRCA2 genes, thus suggesting 
that platinum compounds should be preferred treatment options in this patient population6. While such results 
await confirmation in larger studies, new predictive biomarkers are needed that are low-cost, routinely assessable 
with standardized techniques, well reproducible across different laboratories, and capable of predicting benefit 
from platinum-based ChT.
Many evidences highlight the importance of immune system activation in TNBC control: first, 
tumor-infiltrating lymphocytes (TILs) and other immune markers correlate with higher rates of pathological 
complete response (pCR), as well as with better patient disease-free survival (DFS) and OS, after neoadjuvant 
ChT10–13; second, the programmed death 1 (PD-1) inhibitor pembrolizumab and the PD-1 ligand (PD-L1) 
inhibitor atezolizumab are active in subgroups of heavily pre-treated TNBC patients14–16; lastly, combining 
nab-paclitaxel with atezolizumab has shown promising clinical activity in TNBC17,18, and taxanes-atezolizumab 
combinations are being evaluated in larger prospective trials [NCT02425891; NCT03125902].
Recent studies have revealed the prognostic role of parameters that reflect systemic inflammation or the status 
of antitumor immunity, such as the neutrophil-to-lymphocyte ratio (NLR) and the platelet-to-lymphocyte ratio 
(PLR), in different solid malignancies, including colorectal, renal and lung carcinomas19,20. High NLR has also 
been associated with an increased risk of death in heterogeneous BC patient populations21, including patients 
with limited-stage TNBC22,23. However, none of these studies specifically assessed the role of NLR in mTNBC 
and, even in those studies including different proportions of patients with mBC (4.2–13.9%), subgroup analyses 
in specific tumor biology subgroups, or based on the type of ChT, were not reported24–28.
In this work, we assessed for the first time the potential role of NLR and PLR as biomarkers predictive of PFS 
in mTNBC patients treated with platinum-based ChT. As a control population, we analysed data from patients 
with hormone receptor-positive HER2-negative (HR+ HER2−) mBC treated with the same platinum-containing 
regimens. To discriminate between a predictive and a purely prognostic role of these parameters, we also evalu-
ated patient OS.
Results
Patient characteristics. Between July 2007 and July 2017, 62 mTNBC patients were treated at our 
Institution with platinum-based ChT combinations. Among these patients, 57 fulfilled the inclusion criteria and 
were evaluable for the biomarkers of interest. At the moment of data lock and analysis, 53 (93%) patients had 
progressed and 48 (84%) had died.
Characteristics of evaluated patients are described in Table 1. Median age among TNBC patients was 56 years 
(range 33.7–78.9). Most patients (84%) received carboplatin-paclitaxel ChT, while the remaining ones (16%) were 
treated with the carboplatin-gemcitabine combination. All mTNBC patients received platinum-containing ChT 
as their first- (88%) or second-line (12%) treatment.
In the control population of HR+ HER2− patients, median age was 58 years (range 29.8–79.3); 
most patients (75.7%) were treated with carboplatin-paclitaxel and the remaining ones (24.3%) received 
carboplatin-gemcitabine. Of these patients, 70.3% received platinum-containing ChT as their first- or second-line 
therapy.
Impact of NLR and PLR on PFS. Median PFS in the TNBC population was 204 days. Higher neutrophils 
(4000/µl) were associated with non-significantly lower PFS (p = 0.081), while platelets above 300000/µl or lym-
phocytes below 1500/µl correlated with significantly shorter PFS (p = 0.041 and p = 0.005, respectively) (Fig. S1).
TNBC
ER/PgR-positive 
HER2-negative
N. pts 57 148
Median age (years, range) 56 (33.7–78.9) 58 (29.8–79.3)
Previous taxane exposure
   Yes 43 (75.4%) 102 (68.9%)
   No 14 (24.6%) 46 (31.1%)
N. chemotherapy line
   1st–2nd 57 (100%) 104 (70.3%)
   >2nd 0 (0%) 44 (29.7%)
N. disease sites:
   1–2 sites 36 (63.2%) 88 (59.5%)
   >2 sites 21 (36.8%) 60 (40.5%)
Presence of visceral disease 37 (65%) 99 (66.9%)
Type of treatment
   paclitaxel 48 (84.2%) 112 (75.7%)
   gemcitabine 9 (15.8%) 36 (24.3%)
Maintenance therapy 14 (24.6%) 65 (43.9%)
Table 1. Characteristics of patients with mTNBC and the HR+ mBC control population.
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Median age among metastatic triple negative breast 
cancer (TNBC) patients was 56 years (range 33.7–
78.9).  
Most patients (84%) received chemotherapy with 
carboplatin plus paclitaxel, while the remaining ones 
(16%) were treated with the carboplatin plus 
gemcitabine combination. All metastatic TNBC 
patients received platinum-containing chemotherapy as 
their first- (88%) or second-line (12%) treatment. 
In the control population of patients with ER 
positive/HER2 negative metastatic breast cancer, 
median age was 58 years (range 29.8–79.3); most 
patients (75.7%) were treated with carboplatin plus 
paclitaxel and the remaining ones (24.3%) received 
carboplatin plus gemcitabine. Of these patients, 70.3% 
received platinum-based chemotherapy as their first- or 
second-line therapy. 
3.2 Impact of NLR and PLR on PFS  
Median progression free survival (PFS) in the triple 
negative breast cancer population was 204 days.  
Higher neutrophils (4000/µl) were associated with non-
significantly lower PFS (p = 0.081), while platelets 
above 300000/µl or lymphocytes below 1500/µl 
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correlated with significantly shorter PFS (p = 0.041 
and p = 0.005, respectively) (Fig. 3) 
  
  
   
 
   
 
Figure 3. Kaplan-Meier curves of progression free survival 
(PFS) according to baseline neutrophils (A), platelets (B) 
and lymphocytes (C) counts 
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Suppl. Fig. 1  Kaplan-Meier curves of progression free survival (PFS) according to 
baseline neutrophil (A), platelet (B) and lymphocytes (C) counts. 
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We then investigated the potential predictive role of 
NLR and PLR. Based on previous studies, we chose a 
NLR threshold of 2.5 and a PLR threshold of 200 (30, 
34). Both NLR and PLR were inversely associated 
with patient age (p < 0.001 and p = 0.048, 
respectively), while they did not correlate with 
previous taxane exposure (p = 0.076 and p = 0.68, 
respectively), presence of visceral disease (p = 0.9 and 
p = 0.6, respectively), type of platinum-based 
chemotherapy received (p = 0.48 and p = 0.7, 
respectively) and number of metastatic sites (p = 0.22 
and p = 0.39, respectively) (shown in Table 2). 
 
 
Table 2. Characteristics of metastatic TNBC patients by 
NLR and PLR.                              
Pts = patients; ChT = chemotherapy. *Fisher’s exact test. 
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We then investigated the potential predictive role of NLR and PLR. Based on previous studies, we chose a 
NLR threshold of 2.5 and a PLR threshold of 20021,29. Both NLR and PLR were inversely associated with patient 
age (p < 0.001 and p = 0.048, respectively), while they did not correlate with previous taxane exposure (p = 0.076 
and p = 0.68, respectively), presence of visceral disease (p = 0.9 and p = 0.6, respectively), type of ChT received 
(p = 0.48 and p = 0.7, respectively) and number of metastatic sites (p = 0.22 and p = 0.39, respectively) (Table 2). 
Finally, high NLR correlated with lower probability of receiving maintenance ChT (p = 0.017), while PLR did not 
(p = 0.097).
Median PFS was 304 days in patients with NLR < 2.5 and 158 days in those with NLR ≥ 2.5 (HR 3.25, 95% 
CI 1.72–6.25; p < 0.001) (Fig. 1A). Similar results were obtained by choosing a threshold of 3.3 (274 vs 148 days, 
p < 0.0001) or 2 (309 vs 186 days, p = 0.0015) (data not shown). Regarding the PLR, PFS was longer in patients 
with baseline PLR < 200 as compared to PLR ≥ 200 (HR 2.75, 95% CI 1.52–4.99; p < 0.001) (Fig. 1B). Baseline 
LMR ≥ 4.5 was also associated with significantly better PFS in TNBC patients, although the association was less 
strong than in the case of NLR and PLR (HR 2.22, 95% CI 1.22–4.05, p = 0.009; data not shown).
When the same parameters were evaluated before the administration of the third treatment cycle, NLR < 2.5 
was still associated with reduced risk of disease progression (140 vs 262 days, p < 0.001), while PLR < 200 was not 
(259 vs 204 days, p = 0.48) (data not shown).
In the control population of HR+ HER2− mBC patients, mPFS was 220 days. Baseline higher NLR and PLR 
were non-significantly associated with the risk of disease progression (p = 0.21 and p = 0.29) (Fig. 1C and D).
Independent predictive role of NLR and PLR on PFS. Factors associated with the risk of disease pro-
gression in mTNBC were: previous exposure to taxanes, the presence of visceral metastases, having received 
maintenance ChT, NLR ≥ 2.5 and PLR ≥ 200 (Fig. 2A). As previously described27, NLR and PLR positively cor-
related with each other (Pearson coefficient regression = 0.49; p < 0.001); therefore, only one of these parameters 
was evaluated at multivariable analysis.
In the multivariable model including NLR as a covariate, NLR ≥ 2.5 was associated with significantly lower 
PFS (HR 2.65; p = 0.004), while other covariates were not statistically significantly associated with PFS (Fig. 2B). 
When we tested PLR at multivariable analysis, PLR ≥ 200 was independently associated with poorer patient prog-
nosis (HR 2.33; p = 0.007), while the other covariates were not, with the exception of maintenance ChT, which 
correlated with reduced risk of progression (HR 0.45; p = 0.027) (data not shown).
Impact of peripheral blood parameters on OS. Median OS was 483 days in mTNBC patients and 653 
days in the control population of HR+ HER2− patients.
In mTNBC patients, mOS was significantly longer in patients with NLR < 2.5 compared to those with 
NLR ≥ 2.5 (p = 0.01), while PLR values were not associated with mOS (p = 0.14) (Fig. 3, upper panels). In HR+ 
HER2− BC patients, both NLR < 2.5 and PLR < 200 were associated with significantly better mOS (p = 0.023 and 
p = 0.003, respectively) (Fig. 3, lower panels).
At univariate analysis, factors associated with worse OS in mTNBC patients were NLR ≥ 2.5 and having 
received gemcitabine in combination with carboplatin, while maintenance ChT correlated with better PFS 
Total (n = 57) NLR <2.5 (n = 25) NLR ≥2.5 (n = 32)
p value
PLR <200 (n = 34) PLR ≥200 (n = 23)
p valueN (%) N (%) N (%) N (%) N (%)
Pts age
   <50 yrs 21 (36.8%) 3 (5.2%) 18 (31.6%)
<0.001
9 (15.8%) 12 (21%)
0.048
   >50 yrs 36 (63.2%) 22 (38.6%) 14 (24.6%) 25 (43.9%) 11 (19.3%)
Previous taxane
   Yes 43 (75.4%) 16 (28%) 27 (47.4%)
0.076
25 (43.8%) 18 (31.6%)
0.68
   No 14 (24.6%) 9 (15.8%) 5 (8.8%) 9 (15.8%) 5 (8.8%)
Visceral disease
   Yes 37 (64.9%) 16 (28%) 21 (36.8%)
0.9
23 (40.3%) 14 (24.6%)
0.6
   No 20 (35.1%) 9 (15.8%) 11 (19.4%) 11 (19.3%) 9 (15.8%)
N. metastatic sites
   1–2 36 (63.2%) 18 (31.6%) 18 (31.6%)
0.22
23 (40.3%) 13 (22.8%)
0.39
   >2 21 (36.8%) 7 (12.3%) 14 (24.5%) 11 (19.3%) 10 (17.6%)
ChT type
   Taxane 48 (84.2%) 20 (35.1%) 28 (49.1%)
0.48*
28 (49.1%) 20 (35.1%)
0.7*
   Gemcitabine 9 (15.8%) 5 (8.8%) 4 (7%) 6 (10.5%) 3 (5.3%)
Maintenance ChT
   Yes 14 (24.6%) 10 (17.6%) 4 (7%)
0.017
11 (19.3%) 3 (5.3%)
0.097
   No 43 (75.4%) 15 (26.3%) 28 (49.1%) 23 (40.3%) 20 (35.1%)
Table 2. Characteristics of mTNBC patients by NLR and PLR. Pts = patients; ChT = chemotherapy. *Fisher’s 
exact test.
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Finally, high NLR correlated with lower probability of 
receiving maintenance chemotherapy (p = 0.017), 
while PLR did not (p = 0.097). 
Median PFS was 304 days in patients with NLR < 2.5 
and 158 days in those with NLR ≥ 2.5 (HR 3.25, 95% 
CI 1.72–6.25; p < 0.001) (Fig. 4A). Similar results 
were obtained by choosing a threshold of 3.3 (274 vs 
148 days, p < 0.0001) or 2 (309 vs 186 days, p = 
0.0015) (data not shown). Regarding the PLR, PFS was 
longer in patients with baseline PLR < 200 as 
compared to PLR ≥ 200 (HR 2.75, 95% CI 1.52–4.99; 
p < 0.001) (Fig. 4B). Baseline LMR ≥ 4.5 was also 
associated with significantly better PFS in TNBC 
patients, although the association was less strong than 
in the case of NLR and PLR (HR 2.22, 95% CI 1.22–
4.05, p = 0.009; data not shown). 
When the same parameters were evaluated before the 
administration of the third treatment cycle, NLR < 2.5 
was still associated with reduced risk of disease 
progression (140 vs 262 days, p < 0.001), while PLR < 
200 was not (259 vs 204 days, p = 0.48) (data not 
shown). 
In the control population of ER positive/ HER2 
negative metastatic BC patients, median PFS was 220 
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days. Baseline higher NLR and PLR were non-
significantly associated with the risk of disease 
progression (p = 0.21 and p = 0.29) (Fig. 4 C and D). 
 
 
Figure 4. Kaplan-Meier curves of progression free survival 
(PFS) of TNBC (A and B) and ER positive/HER2 negative 
(C and D) mBC patients according to baseline NLR (A and 
C) and PLR (B and D). 
 
3.3 Independent predictive role of NLR and PLR on 
progression free survival (PFS).  
Factors associated with the risk of disease progression 
in metastatic TNBC were: previous exposure to 
taxanes, the presence of visceral metastases, having 
received maintenance chemotherapy, NLR ≥ 2.5 and 
PLR ≥ 200 (Fig. 5A). As previously described27, NLR 
and PLR positively correlated with each other (Pearson 
www.nature.com/scientificreports/
4SCIENTIFIC REPORTS |  (2018) 8:8703  | DOI:10.1038/s41598-018-27075-z
(Fig. 4A). At multivariable analysis, NLR ≥ 2.5 and gemcitabine treatment were independently associated with 
worse outcomes (Fig. 4B).
In the control population, factors associated with lower OS were: NLR ≥ 2.5, presence of visceral disease, 
previous taxane exposure and more advanced (>2nd) treatment lines, while having received maintenance ther-
apy correlated with lower risk of death (Fig. S2, upper panel). At multivariable analysis, high NLR and visceral 
involvement were independently associated with lower survival, while maintenance treatment correlated with 
better outcome (Fig. S2, lower panel).
Impact of germline BRCA 1/2 mutations on TNBC patient PFS. Among mTNBC patients included 
in our study, only 19 had undergone analysis of germline mutations of the BRCA1/2 genes. Of them, 6 were car-
riers of a pathogenic germline BRCA1/2 mutation, while the remaining 13 patients had wild-type BRCA1/2 gene. 
Median PFS was 126 days in carriers of BRCA1/2 mutations and 163 days in non-mutated ones (HR = 1.09, 50% 
CI 0.38–3.12, p = 0.87).
Discussion
Although platinum-based ChT is active against mTNBC, many patients fail to respond, and no biomark-
ers are currently available to predict treatment effectiveness. In this study, we found for the first time an asso-
ciation between higher NLR or PLR and worse PFS in mTNBC patients receiving carboplatin-paclitaxel 
or carboplatin-gemcitabine, but not in a control population of HR+ HER2− patients treat d with the same 
regimens.
The fact that specific blood cell populations reflect the inflammatory/immune contexture is quite a 
well-established concept. Indeed, high neutrophils can be associated with systemic inflammation or immune 
suppression30; high platelets reflect systemic inflammation as well, but can be also associated with increased meta-
statization of neoplastic cells via platelet clots30–32; finally, low lymphocyte counts can be associated with impaired 
activation of adaptive immunity or poor nutritional status33,34. In this study, the association between clinical 
Figure 1. Kaplan-Meier curves of progression free survival (PFS) of TNBC and HR+ mBC patients according 
to baseline NLR (A and C) and PLR (B and D).
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(Fig. 4A). At multivariable analysis, NLR ≥ 2.5 and gemcitabine treatment were independently associated with 
worse outcomes (Fig. 4B).
In the control population, factors associated with lower OS were: NLR ≥ 2.5, presence of visceral disease, 
previous taxane exposure and more advanced (>2nd) treatment lines, while having received maintenance ther-
apy correlated with lower risk of death (Fig. S2, upper panel). At multivariable analysis, high NLR and visceral 
involvement were independently associated with lower survival, while maintenance treatment correlated with 
better outcome (Fig. S2, lower panel).
Impact of germline BRCA 1/2 mutations on TNBC patient PFS. Among mTNBC patients included 
in our study, only 19 had undergone analysis of germline mutations of the BRCA1/2 genes. Of them, 6 were car-
riers of a pathogenic germline BRCA1/2 mutation, while the remaining 13 patients had wild-type BRCA1/2 gene. 
Median PFS was 126 days in carriers of BRCA1/2 mutations and 163 days in non-mutated ones (HR = 1.09, 50% 
CI 0.38–3.12, p = 0.87).
Discussion
Although platinum-based ChT is active against mTNBC, many patients fail to respond, and no biomark-
ers are currently avail ble to predict treatment effectiveness. I  this study, we f und f r the first time an asso-
ciation between higher NLR or PLR nd wors  PFS in mTNBC patients receiving carboplatin-paclitaxel 
or carboplatin-gemcitabine, but not in a control population of HR+ HER2− patients treated with the same 
regimens.
The fact that specific blood cell populations reflect the inflammatory/immune contexture is quite a 
well-established concept. Indeed, high neutrophils can be associated wi h syste ic inflammation or immune 
suppression30; high platelets reflect systemic inflammation as well, but can be also associated with i creased meta-
tatization of neoplastic cells via platel t clots30–32; finally, low lymphocyte counts can be associated with impaired 
activ f adaptive immunity or poor nutritio l status33,34. In this st dy, the associat on between cl nical 
Figure 1. Kaplan-Meier curves of progression free survival (PFS) of TNBC and HR+ mBC patients according 
to baseline NLR (A and C) and PLR (B and D).
	 21	
coefficient regression = 0.49; p < 0.001); therefore, 
only one of these parameters was evaluated at 
multivariable analysis. 
In the multivariable model including NLR as a 
covariate, NLR ≥ 2.5 was associated with significantly 
lower PFS (HR 2.65; p = 0.004), while other covariates 
were not statistically significantly associated with PFS 
(Fig. 5B). 
 
Figure 5. Forest plot illustrating the results of 
univariable (A) and multivariable (B) analysis of 
covariates associated with the risk of disease 
progression in mTNBC. 
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outcomes and NLR/PLR was stronger than in the case of individual cell counts. This is not surprising, since 
parameter combinations are more stable to changes in single parameters (e.g. neutrophils or platelets can increase 
during acute infections or glucocorticoid administration) and may capture more aspects of the tumor-immune 
system interplay. Notably, the HRs associated to NLR and PLR at multivariable analysis for PFS were similar, and 
these parameters also correlated with each other. This suggests that both NLR and PLR well reflect the inflamma-
tory/immune contexture in mTNBC, and may be redundant as predictive biomarkers.
In TNBC patients, higher NLR correlated with lower OS, but the association was weaker than in the case of 
PFS; moreover, no statistically significant association was found between PLR and OS. These results can be due to 
the fact that, different from PFS, OS is affected by the whole treatment course, including therapies administered 
after platinum-based ChT; therefore, the association between NLR/PLR and PFS during platinum-based ChT 
could be diluted by subsequent treatments for which the same parameters are not predictive.
Conversely, both NLR and PLR correlated with lower OS in the control population of HR+ HER2− mBC 
patients, despite the fact that they were not predictive of PFS during platinum-based ChT. This could be due to 
the fact that NLR and PLR are associated to benefit from treatments administered after platinum ChT; therefore, 
Figure 2. Forest plot illustrating the results of univariable (A) and multivariable (B) analysis of covariates 
associated with the risk of disease progression in mTNBC.
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When we tested PLR at multivariable analysis, PLR ≥ 
200 was independently associated with poorer patient 
prognosis 
(HR 2.33; p = 0.007), while the other covariates were 
not, with the exception of maintenance chemotherapy, 
which correlated with reduced risk of progression (HR 
0.45; p = 0.027) (data not shown). 
Impact of peripheral blood parameters on overall 
survival (OS)  
Median overall survival (OS) was 483 days in 
metastatic triple negative breast cancer patients and 
653 days in the control population of ER 
positive/HER2 negative breast cancer patients.  
In metastatic triple negative breast cancer, median 
overall survival (mOS) was significantly longer in 
patients with NLR < 2.5 compared to those with NLR 
≥ 2.5 (p = 0.01), while PLR values were not associated 
with statistically significant differences in mOS (p = 
0.14) (Fig. 6A and B).  
In ER positive/HER2 negative breast cancer patients 
(control arm), both NLR < 2.5 and PLR < 200 were 
associated with significantly better mOS (p = 0.023 
and p = 0.003, respectively) (Fig. 6 C and D). 
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Figure 6. Kaplan-Meier curves of overall survival (OS) of 
TNBC (A and B) and ERpositive/HER2 negative (C and D) 
mBC patients according to baseline NLR (A and C) and 
PLR (B and D)  
At univariate analysis, factors associated with worse 
overall survival in metastatic triple negative breast 
cancer patients were:  
- NLR ≥ 2.5  
- having received gemcitabine in combination with 
carboplatin,  
while maintenance chemotherapy correlated with better 
progression free survival (Fig. 7A). At multivariable 
analysis, NLR ≥ 2.5 and gemcitabine treatment were 
independently associated with worse outcomes (Fig. 
7B). 
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their effect may only emerge when evaluating OS as an endpoint. Alternatively, these parameters may be generally 
prognostic in HR+ BC, but not predictive of benefit from specific treatments. Based on our data, we are unable to 
discriminate between these two hypotheses.
Studies conducted in recent years have revealed a previously unrecognized complexity of the number and 
functional status of different immune system subpopulations35,36. For instance, circulating blood lymphocytes 
include phenotypically and functionally different cells, such as CD8+ cytotoxic lymphocytes, regulatory T cells 
and exhausted lymphocytes, whose balance can determine the predominantly antitumor or protumor activity 
of adaptive immunity35. In parallel, blood monocytes include both cells that differentiate into antitumor M1 
macrophages at the tissue level, and myeloid-derived suppressive cells (MDSCs) that exert pro-tumor effects by 
inhibiting the activity of antitumor T lymphocytes37. Coherently with a previous research in localized TNBC23, in 
this study we also found an association between the LMR and patient PFS, but this was weaker than in the case of 
NLR and PLR, and similar to the association between absolute lymphocyte counts and PFS. This finding suggests 
that monocytes may be poorly predictive of survival in mTNBC.
Investigating the potential association between specific immune cell populations and patient prognosis could 
reveal more reliable and predictive parameters to improve treatment selection in mTNBC. In this perspective, we 
recently started a prospective observational study to assess the role of baseline immunological parameters, as well 
as their on-treatment modifications, on the PFS of mTNBC patients receiving platinum-based ChT.
In this study, we did not find any significant difference in PFS duration between patients with or without 
BRCA1/2 germline mutations, which have recently emerged as ass ciated with higher tumor response rates dur-
ing carboplatin ChT6. However, the number of subjects amenable to this analysis was too low, and larger stud-
ies are required to assess the independent predictive role of NLR/PLR and BRCA1/2 mutations on the PFS of 
mTNBC receiving platinum-based ChT.
Strengths of this study consist in the monocentric patient cohort, which guarantees more reproducible assess-
ment of tumor response and coherent collection of patient laboratory data by different investigators, as well as the 
homogeneity of ChT regimens used and the TNBC patient cohort. In particular, the fact that all TNBC patients 
received carboplatin-based ChT as first- or second-line treatment makes our results more robust compared to 
previously published data in patients treated with different regimens in different treatment lines. Weaknesses of 
our study consist in the retrospective design, the limited number of TNBC patients included in the analysis and 
the lack of data on tumor-infiltrating immune cells, which did not allow us to establish a direct, mechanistic link 
Figure 3. Kaplan-Meier curves of overall survival (PFS) of TNBC and HR+ mBC patients according to 
baseline NLR (A and C) and PLR (B and D).
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their effect may only emerge when evaluating OS as an endpoint. Alternatively, these parameters may be generally 
prognostic in HR+ BC, but not predictive of benefit from specific treatments. Based on our data, we are unable to 
discriminate between these two hypotheses.
Studies conducted in recent years have revealed a previously unrecognized complexity of the number and 
functional status of different immune system subpopulations35,36. For instance, circulating blood ly phocytes 
include phenotypically and functio ally different cells, such as CD8+ cytotoxic lymphocytes, regulatory T c lls 
a d exhausted lymphocytes, whose balance ca  d termine the predominantly antitumor or protumor activity 
of adaptive immunity35. In parallel, blood mo ocytes i clude both cells that differentiate into antitumor M1 
macro hages at the tissue level, and myeloid-derived uppressive cells (MDSCs) that exert pro-tumor effects by 
inhibiting the c ivity of antitumor T lymphocytes37. Cohe ntly with a previous research in localized TNBC23, in 
this study we also found  association between the LMR and patient PFS, but thi  was weaker than in the case of 
NLR an  PLR, and simil r to the ss ciation betw en absolute lymphocyte counts and PFS. This finding suggests 
that monocytes may be poorly predict ve f survival in mTNBC.
Investigating the potential assoc a on between specific immune cell populations and patient prognosis could 
reveal more reliable and predictive parameters to improve treatment selection in mTNBC. In this perspective, we 
c ntly start d  prospective obs rv tional study to assess the role of baseline immunological parameters, as ll 
as their on-tr atment modifications, on the PFS of mTNBC patients rec iving plati um-based ChT.
In this s udy, we did not find any significant difference in PFS duration be ween p tients with or without 
BRCA1/2 germline mutati ns, which have rece tly em rged as associated with higher tumor response rates d r-
ing carboplatin ChT6. However, the number of subjects amen ble to this an lysis was to  low, a d larg r stud-
ies are required to assess the indepe dent predictive role of NLR/PLR and BRCA1/2 mutations on the PFS of 
mTNBC receiving platinum-based ChT.
Strengths of this study consist in t e monocentric patient cohort, which guarantees more reproducible assess-
ment of tumor response and coherent collection of patient lab ratory data by different investigat rs, as well as the 
homogeneity of ChT regimens used and the TNBC patient c hort. In particular, the fact that all TNBC patients 
received carboplatin-based ChT as first- or second-line treatment makes our results more robust compared to 
previously published data in patients treated with different regimens in different treatment lines. Weaknesses of 
our study consist in the retrospective design, the limited number of TNBC patients included in the analysis and 
the lack of data on tumor-infiltrating immune cells, which did not allow us to establish a direct, mechanistic link 
Figure 3. Kaplan-Meier curves of overall survival (PFS) of TNBC and HR+ mBC patients according to 
baseline NLR (A and C) a d PLR (B and D).
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Figure 7: Forest plot illustrating the results of univariable 
(A) and multivariable (B) analysis of covariates associated 
with the overall survival in mTNBC. 
 
In the control population, factors associated with worse 
overall survival were:  
- NLR ≥ 2.5,  
- presence of visceral disease,  
- previous taxane exposure  
- more advanced (>2nd) treatment lines,  
while having received maintenance therapy correlated 
with lower risk of death (Fig 8A).  
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between peripheral blood parameters and immune cell populations in tumor microenvironment or directly infil-
trating the tumor. However, the NLR and PLR calculated at the initiation of platinum-based ChT may reflect the 
systemic inflammatory and immunological status much more reliably than immune cells detected in tumor speci-
mens biopsied/removed months/years before treatment administration. Moreover, the NLR and PLR could offer a 
more global picture of the immune contexture, thus circumventing the spatial heterogeneity in tumor-infiltrating 
immune cell populations.
In conclusion, the NLR and PLR are predictive of benefit from platinum-containing ChT specifically in 
mTNBC patients. They also confirm to have a generally prognostic role independently from tumor biology. If 
validated in larger prospective studies, these easy-to-measure parameters could be combined with emerging pre-
dictive biomarkers, such as germline or somatic BRCA 1/2 gene mutations, to improve the selection of mTNBC 
patients more likely to benefit from platinum-based ChT.
Methods
Study setting. This was a monocentric, retrospective study on patients with mTNBC treated between July 
2007 and July 2017 at Fondazione IRCCS Istituto Nazionale dei Tumori (Milan, Italy) with platinum-based ChT. 
Figure 4. Forest plot illustrating the results of univariable (A) and multivariable (B) analysis of covariates 
associated with the overall survival in mTNBC.
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between peripheral blood parameters and immune cell populations in tumor microenvironment or directly infil-
trating the tumor. However, the NLR and PLR calculated at the initiation of platinum-based ChT may reflect the 
systemic inflammatory and immunological status much more reliably than immune cells detected in tumor speci-
mens biopsied/removed months/years before treatment administration. Moreover, the NLR and PLR could offer a 
more global picture of the immune contexture, thus circumventing the spatial heterogeneity in tumor-infiltrating 
immune cell populations.
In conclusion, the NLR and PLR are predictive of benefit from platinum-containing ChT specifically in 
mTNBC patients. They also confirm to have a generally prognostic role independently from tumor biology. If 
validated in larger prospective studies, these easy-to-measure parameters could be combined with emerging pre-
dictive biomarkers, such as germline or somatic BRCA 1/2 gene mutations, to improve the selection of mTNBC 
patients more likely to benefit from platinum-based ChT.
Methods
Study setting. This was a monocentric, retrospective study on patients with mTNBC treated between July 
2007 and July 2017 at Fondazione IRCCS Istituto Nazionale dei Tumori (Milan, Italy) with platinum-based ChT. 
Figure 4. Forest plot illustrating the results of univariable (A) and multivariable (B) analysis of covariates 
associated with the verall survival in mTNBC.
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At multivariable analysis, high NLR and visceral 
involvement were independently associated with lower 
survival, while maintenance treatment correlated with 
better outcome (Fig. 8B).  
 
 
Figure 8. Forest plots illustrating the results of univariable 
(A) and multivariable (B) analysis of covariates associated 
with overall survival in ER positive/HER2 negative 
metastatic BC (control arm)  
 
Impact of germline BRCA 1/2 mutations on TNBC 
patient PFS  
Among metastatic TNBC patients included in our 
study, only 19 had undergone analysis of germline 
Variable                          N Pts Hazard Ratio (95% CI)    Hazard Ratio                                                                              p-value   
(95% CI)
Previous taxane 57      1.79 (1.19-2.69)                                                                                         0.0052
(yes vs no)
Visceral disease               57       1.57 (1.05-2.33)                                                                        0.026
(yes vs no)
ChT type                        57       1.24 (0.8-1.93)                                                                           0.33
(gem vs tax)
N. line                           57       1.51 (1.01-2.26)                                                                                                                0.046
(>2 vs 1-2)
N. metastatic sites          57       1.34 (0.93-1.93)                                                                                                       0.12
(>2 vs 1-2)
Maintenance therapy    57       0.37 (0.25-0.55)                                                                                <0.001
(yes vs no)
NLR                               57        1.52 (1.05-2.2)                                                                  0.025
(high vs low)                                
PLR                                57       1.73 (1.19-2.5)                                                                    0.0036
(high vs low)
0        0.5      1      1.5      2       2.5      3      3.5     4      4.5     5       
Univariable analysis for OS (HR+ HER2-neg)
Suppl. Fig 2  Forest plot illustrating the results of univariable (A) and multivariable (B) analysis of 
covariates associated with the overall survival in HR+ mBC
A
Variable                          N Pts Hazard Ratio (95% CI)    Hazard Ratio                                                                              p-value   
(95% CI)
Previous taxane 57      1.39 (0.88-2.2)                                                                                          0.16
(yes vs no)
Visceral disease               57       1.68 (1.13-2.51)                                                                        0.011
(yes vs no)
N. line                             57       0.88 (0.56-1.38)                                                                0.57
(>2 vs 1-2)
Maintenance therapy    57       0.38 (0.25-0.57)                                                                                <0.001
(yes vs no)
NLR                               57        1.65 (1.13-2.4)                                                                  0.0095
(high vs low)                                
0        0.5      1      1.5      2       2.5      3      3.5     4      4.5     5       
Multivariable analysis for OS (HR+ HER2-neg)B
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mutations of the BRCA1/2 genes. Of them, 6 were 
carriers of a pathogenic germline BRCA1/2 mutation, 
while the remaining 13 patients had wild-type 
BRCA1/2 gene. 
Median PFS was 126 days in carriers of BRCA1/2 
mutations and 163 days in non-mutated ones (HR = 
1.09, 50% CI 0.38–3.12, p = 0.87). 
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4. Discussion 
Although platinum-based chemotherapy is a standard 
treatment for metastatic triple negative breast cancer, 
many patients fail to respond, and no biomarkers are 
currently available to predict treatment effectiveness. 
In this study, we found for the first time an association 
between higher NLR or PLR and worse outcome in 
terms of progression free survival (PFS) in metastatic 
TNBC patients receiving carboplatin plus paclitaxel or 
carboplatin plus gemcitabine therapies, but not in a 
control population of ER positive/HER2 negative 
metastatic breast cancer patients treated with the same 
chemotherapy regimens. 
The fact that specific blood cell populations reflect the 
inflammatory/immune contexture is quite a well-
established concept. Indeed, high neutrophils can be 
associated with systemic inflammation or immune 
suppression (35); high platelets reflect systemic 
inflammation as well, but can be also associated with 
increased metastatization of neoplastic cells via platelet 
clots (30, 32); finally, low lymphocyte counts can be 
associated with impaired activation of adaptive 
immunity or poor nutritional status (33,34). In this 
study, the association between clinical outcomes and 
NLR/PLR was stronger than in the case of individual 
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cell counts. This is not surprising, since parameter 
combinations are more stable to changes in single 
parameters (e.g. neutrophils or platelets can increase 
during acute infections or glucocorticoid 
administration) and may capture more aspects of the 
tumor-immune system interplay. Notably, the HRs 
associated to NLR and PLR at multivariable analysis 
for PFS were similar, and these parameters also 
correlated with each other. This suggests that both 
NLR and PLR well reflect the inflammatory/ immune 
contexture in mTNBC, and may be redundant as 
predictive biomarkers. 
In TNBC patients, higher NLR correlated with lower 
OS, but the association was weaker than in the case of 
PFS; moreover, no statistically significant association 
was found between PLR and OS. These results can be 
due to the fact that, different from PFS, OS is affected 
by the whole treatment course, including therapies 
administered after platinum-based chemotherapy; 
therefore, the association between NLR/PLR and PFS 
during platinum-based chemotherapy could be diluted 
by subsequent treatments for which the same 
parameters are not predictive. 
Conversely, both NLR and PLR correlated with lower 
OS in the control population of ER positive/HER2 
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negative metastatic breast cancer patients, despite the 
fact that they were not predictive of PFS during 
platinum-based treatment. This could be due to the fact 
that NLR and PLR are associated to benefit from 
treatments administered after platinum containing 
chemotherapy; therefore, their effect may only emerge 
when evaluating OS as an endpoint. Alternatively, 
these parameters may be generally prognostic in ER 
positive/HER2 negative breast cancer, but not 
predictive of benefit from specific treatments. Based 
on our data, we are unable to discriminate between 
these two hypotheses. Studies conducted in recent 
years have revealed a previously unrecognized 
complexity of the number and functional status of 
different immune system subpopulations (36,37). For 
instance, circulating blood lymphocytes include 
phenotypically and functionally different cells, such as 
CD8+ cytotoxic lymphocytes, regulatory T cells and 
exhausted lymphocytes, whose balance can determine 
the predominantly antitumor or protumor activity of 
adaptive immunity35. In parallel, blood monocytes 
include both cells that differentiate into antitumor M1 
macrophages at the tissue level, and myeloid-derived 
suppressive cells (MDSCs) that exert pro-tumor effects 
by inhibiting the activity of antitumor T lymphocytes 
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(37). Coherently with a previous research in localized 
TNBC (23), in this study we also found an association 
between the LMR and patient PFS, but this was weaker 
than in the case of NLR and PLR, and similar to the 
association between absolute lymphocyte counts and 
PFS. This finding suggests that monocytes may be 
poorly predictive of survival in metastatic TNBC. 
Investigating the potential association between specific 
immune cell populations and patient prognosis could 
reveal more reliable and predictive parameters to 
improve treatment selection in metastatic TNBC. In 
this perspective, we recently started a prospective 
observational study to assess the role of baseline 
immunological parameters, as well as their on-
treatment modifications, on the PFS of metastatic 
TNBC patients receiving platinum-based 
chemotherapy. In this study, we did not find any 
significant difference in PFS duration between patients 
with or without BRCA1/2 germline mutations, which 
have recently emerged as associated with higher tumor 
response rates during carboplatin chemotherapy. 
However, the number of subjects amenable to this 
analysis was too low, and larger studies are required to 
assess the independent predictive role of NLR/PLR and 
BRCA1/2 mutations on the PFS of metastatic triple 
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negative breast cancer patients receiving platinum-
based therapies. 
Strengths of this study consist in the monocentric 
patient cohort, which guarantees more reproducible 
assessment of tumor response and coherent collection 
of patient laboratory data by different investigators, as 
well as the homogeneity of chemotherapy regimens 
used and the TNBC patient cohort. In particular, the 
fact that all TNBC patients received carboplatin-based 
chemotherapy as first- or second-line treatment makes 
our results more robust compared to previously 
published data in patients treated with different 
regimens in different treatment lines. Weaknesses of 
this study consist in the retrospective design, the 
limited number of TNBC patients included in the 
analysis and the lack of data on tumor-infiltrating 
immune cells, which did not allow us to establish a 
direct, mechanistic link between peripheral blood 
parameters and immune cell populations in tumor 
microenvironment or directly infiltrating the tumor. 
However, the NLR and PLR calculated at the initiation 
of platinum-based chemotherapy may reflect the 
systemic inflammatory and immunological status much 
more reliably than immune cells detected in tumor 
specimens biopsied/removed months/years before 
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treatment administration. Moreover, the NLR and PLR 
could offer a more global picture of the immune 
contexture, thus circumventing the spatial 
heterogeneity in tumor-infiltrating immune cell 
populations. 
In conclusion, the NLR and PLR are predictive of 
benefit from platinum-containing chemotherapy 
specifically in metastatic triple negative breast cancer 
patients. They also confirm to have a generally 
prognostic role independently from tumor biology. If 
validated in larger prospective studies, these easy-to-
measure parameters could be combined with emerging 
predictive biomarkers, such as germline or somatic 
BRCA 1/2 gene mutations, to improve the selection of 
metastatic TNBC patients more likely to benefit from 
platinum-based chemotherapy.  
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